Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alpine Immune Sciences, Inc. - Common Stock
(NQ:
ALPN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alpine Immune Sciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
September 12, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
September 05, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
September 05, 2023
From
Alpine Immune Sciences, Inc
Via
Business Wire
Analyst Expectations for Alpine Immune Sciences's Future
↗
August 31, 2023
Via
Benzinga
Recap: Alpine Immune Sciences Q1 Earnings
↗
May 11, 2023
Via
Benzinga
Earnings Preview: Alpine Immune Sciences
↗
March 22, 2023
Via
Benzinga
Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)
August 30, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
August 22, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Inc. (NASDAQ: ALPN) Records 52-Week High Tuesday Morning
August 15, 2023
Via
Investor Brand Network
Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
August 14, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
May 19, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Reports First Quarter 2023 Financial Results
May 11, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference
May 01, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 23, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Earnings Scheduled For March 23, 2023
↗
March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.
Via
Benzinga
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
March 20, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
March 16, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results
March 15, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
February 28, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference
February 09, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
↗
January 19, 2023
Via
Benzinga
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
November 07, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting
November 03, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition
November 03, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences
October 26, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death
↗
October 24, 2022
Via
Benzinga
Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)
October 24, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
US Stock Futures Edge Higher; All Eyes On Fed Decision
↗
September 21, 2022
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade on Wednesday after recording losses on Tuesday. The Dow Jones closed lower by more than 300 points, while the Nasdaq...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
